查找临床试验
已按「甲状腺眼病」检索，对应国际通用词 thyroid eye disease
共找到 29 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:03，每 5 分钟自动同步Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
China
年龄 18 Years – 75 Years
Minghui Pharmaceutical (Hangzhou) Ltd
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
China
年龄 18 Years – 80 Years
Shanghai Changzheng Hospital
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
China
年龄 18 Years – 65 Years
Shanghai Zhongshan Hospital
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
China
年龄 18 Years – 75 Years
The First Affiliated Hospital of Xiamen University
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
Taiwan
年龄 20 Years – 不限
Taipei Veterans General Hospital, Taiwan
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
China
年龄 18 Years – 80 Years
Shanghai Changzheng Hospital
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
China
年龄 18 Years – 80 Years
Innovent Biologics (Suzhou) Co. Ltd.
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
China
年龄 18 Years – 80 Years
Innovent Biologics (Suzhou) Co. Ltd.
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
China
年龄 18 Years – 80 Years
Shanghai Changzheng Hospital
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
United States、Poland、Spain、Taiwan
年龄 18 Years – 99 Years
Amgen
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
China
年龄 18 Years – 88 Years
Peking Union Medical College Hospital
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
China
年龄 18 Years – 75 Years
Shanghai Zhongshan Hospital